Is Roivant Sciences (ROIV) the Best Mid Cap Biotech Stock to Buy? [Yahoo! Finance]
Roivant Announces Positive Results for Batoclimab Myasthenia Gravis (MG) and Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Studies
Roivant to Host Investor Webcast at 8:00 AM ET on Wednesday, March 19 to Review Results from Batoclimab Myasthenia Gravis (MG) and Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Programs
Roivant Sciences Ltd. (NASDAQ: ROIV) was upgraded by analysts at Cantor Fitzgerald to a "strong-buy" rating.
Genevant Sciences and Arbutus Biopharma Initiate International Patent Infringement Enforcement Actions Against Moderna [Yahoo! Finance]